Heartland Conference Announces Keynote Speaker

Published in Member Communities on June 01, 2021

Registration opened on Monday, May 3 with early bird pricing through July 15

Mark ScharenbroichVGM & Associates is pleased to announce Mark Scharenbroich, CSP, CPAE, as the keynote speaker for its 20th Heartland Conference scheduled for Sept. 13-15, 2021, in Waterloo, Iowa.

“Mark is phenomenal at creating those authentic connections our members want with their customers and coworkers,” said Sarah Conger, vice president corporate projects at VGM Group, Inc. “His messages are a great fit for our event, as connection is at the core of everything we do at Heartland.”

Best known for his “Nice Bike” story, Mark helps listeners learn about the power of connectivity by taking them on an emotional rollercoaster. His high-impact stories have been described as leaving the audience, “laughing hysterically one moment and touched by tears the next.” However, while his stories and comedic timing are certainly entertaining, his presentations help his listeners form authentic connections that drive loyalty and collaboration, leading to outstanding results.

“Mark has a unique ability to deliver messages and actionable strategy in a way that’s memorable,” Conger continued. “We’re happy to have him, and we’re looking forward to our members hearing him speak.”

As well as being a National Speakers Association’s Hall of Fame inductee, Mark is also an Emmy award winner and an award-winning author for his book, Nice Bike: Making Meaningful Connections on the Road of Life. Learn more about Mark on his website, nicebike.com

If you’d like to see Mark Scharenbroich speak in person at the 20th Anniversary of VGM’s Heartland Conference, visit vgmheartland.com. Registration is open to VGM's membership communities with special early bird pricing until July 15. Click here to register.


TAGS

  1. conference
  2. heartland
  3. hme
  4. vgm

From Our Experts

Medicare Telehealth Flexibilities Extended for CRT Providers thumbnail Medicare Telehealth Flexibilities Extended for CRT Providers Learn how the new Medicare telehealth extension impacts CRT providers. U.S. Rehab's Dan Fedor explains why remote care access remains vital through 2027. Why CRT Providers Are Exploring Home Accessibility in 2026 thumbnail Why CRT Providers Are Exploring Home Accessibility in 2026 Home accessibility is emerging as a major growth path for CRT providers. Explore the trend and learn why strategic, low-risk steps matter. Log in for the full article. Doing More With Less: Home Access in 2026 thumbnail Doing More With Less: Home Access in 2026 Discover how home access remodelers can do more with less using outsourced labor, virtual assessments, standardized materials, and templated scopes. Building a Skilled Home Access Workforce Through Training thumbnail Building a Skilled Home Access Workforce Through Training Discover why training, certifications, and cross-training are essential for home access professionals. VGM Live at Home Spotlight: Chris Moore & the Power of “Age Out Loud” thumbnail VGM Live at Home Spotlight: Chris Moore & the Power of “Age Out Loud” VGM Live at Home spotlights Chris Moore, whose book Age Out Loud and passion for CAPS training inspire professionals to help more people age safely at home. A Note from the President: VGM is Evolving For You thumbnail A Note from the President: VGM is Evolving For You VGM is evolving with purpose by investing in advocacy, technology, and services to support HME providers through industry change and ensure long-term viability. Introducing the F&P Nova Nasal in the United States thumbnail Introducing the F&P Nova Nasal in the United States Fisher and Paykel Healthcare has announced the launch of their newest nasal PAP mask, F&P Nova Nasal, to the United States, for the treatment of obstructive sleep apnea. Introducing the F&P Nova Nasal in the United States thumbnail Introducing the F&P Nova Nasal in the United States Fisher and Paykel Healthcare has announced the launch of their newest nasal PAP mask, F&P Nova Nasal, to the United States, for the treatment of obstructive sleep apnea.